GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (MEX:ATAI) » Definitions » Institutional Ownership

ATAI Life Sciences NV (MEX:ATAI) Institutional Ownership : 2.82% (As of Jun. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ATAI Life Sciences NV Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ATAI Life Sciences NV's institutional ownership is 2.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ATAI Life Sciences NV's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ATAI Life Sciences NV's Float Percentage Of Total Shares Outstanding is 76.28%.


ATAI Life Sciences NV Institutional Ownership Historical Data

The historical data trend for ATAI Life Sciences NV's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Institutional Ownership Chart

ATAI Life Sciences NV Historical Data

The historical data trend for ATAI Life Sciences NV can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 4.32 4.40 4.36 3.76 2.89 2.92 2.88 2.88 2.83 2.82

ATAI Life Sciences NV Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


ATAI Life Sciences NV (MEX:ATAI) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.